Evidence map›Paper›PMID 38832701›Full record

ArticleLeukemia & lymphoma2024

Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL).

Christopher Raymond Frei, Kellie Ryan, Grace Oby Obodozie-Ofoegbu, Amanda Marie Moore, Chengwen Teng, Kana Tai Lucero, Laura Dean Davis, Xavier Francisco Jones, Zohra Nooruddin

Abstract readLetter
In one paragraph

Article in Leukemia & lymphoma, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christopher Raymond FreiCollege of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.ORCID 0000-0002-0692-4787
Kellie RyanAstraZeneca US Medical Affairs, Gaithersburg, MD, USA.
Grace Oby Obodozie-OfoegbuCollege of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.ORCID 0009-0008-9024-7766
Amanda Marie MooreCollege of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.ORCID 0000-0003-2051-1476
Chengwen TengCollege of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.ORCID 0000-0001-9239-2125
Kana Tai LuceroLong School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.ORCID 0009-0009-7052-6546
Laura Dean DavisCollege of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.
Xavier Francisco JonesCollege of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.
Zohra NooruddinLong School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.ORCID 0000-0003-4659-4310

Funding

Institute for Integration of Medicine & Science: A Partnership to Improve HealthUM1TR004538 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ROBERT A CLARK, Kenneth M Hargreaves · 2023 to 2026
$22.3M
Institute for Integration of Medicine & Science: A Partnership to Improve HealthUL1TR002645 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, HARGREAVES, KENNETH M · 2018 to 2022
$20.4M
NCATS NIH HHS UL1 TR002645NCATS NIH HHS UM1 TR004538
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Lymphocytic, Chronic, B-CellUnited States Department of Veterans AffairsVeteransAgedFemaleHumansMaleMiddle AgedUnited States

Identifiers

PMID38832701
PMCPMC11444894

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.